查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1926857

粘菌素甲磺酸鹽注射液市場按適應症、劑型、患者群體、給藥途徑和最終用戶分類－2026-2032年全球預測

Colistimethate Sodium for Injection Market by Indication, Dosage Form, Patient Population, Route Of Administration, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年粘菌素磺酸鹽注射液市場價值為 5,054 萬美元，預計到 2026 年將成長至 5,889 萬美元，到 2032 年將達到 1.1043 億美元，複合年成長率為 11.81%。

關鍵市場統計數據
基準年 2025 5054萬美元
預計年份：2026年 5889萬美元
預測年份 2032 1.1043億美元
複合年成長率 (%) 11.81%

深入介紹注射甲磺酸鹽鈉：說明其臨床應用、給藥途徑、製劑選擇和患者照護環境

注射用硫酸粘菌素鈉在現代感染疾病管理中扮演獨特的角色，主要用於治療難治性革蘭氏陰性病菌感染。其藥理特性和臨床效用在多重抗藥性限制第一線藥物療效的情況下尤其重要。硫酸粘菌素鈉最初被視為最後一線治療藥物，但隨著給藥策略和方法的改進，以及對最容易獲益患者群體的深入了解，其臨床應用已日趨成熟。

抗菌素抗藥性、綜合管理、製劑創新以及對供應鏈韌性日益成長的期望，共同推動了變革性變革。

隨著多種因素的共同作用，粘菌素甲磺酸鈉的市場模式正在發生變化，這些因素正在改變臨床實踐、供應鏈和商業策略。抗生素抗藥性的趨勢仍然是主要的臨床促進因素，促使醫生和醫療機構透過改進給藥方案並在條件允許的情況下實施治療藥物監測來維持療效。同時，抗菌藥物管理計畫（ASP）的角色正在從諮詢安全隔離網閘，影響藥物使用模式，並推廣最佳化給藥方案，例如在特定嚴重患者中使用持續輸注，從而在最大限度提高動態暴露的同時降低毒性風險。

近期關稅變化對無菌注射劑供應鏈、籌資策略、採購趨勢和國內生產獎勵的累積影響

關稅制度和跨境貿易趨勢的政策變化正對無菌注射劑供應鏈產生實際的影響，粘菌素鈉也不例外。原料藥、輔料和包裝組件關稅結構的調整增加了成品的到岸成本，促使生產者重新評估其籌資策略。隨著進口成本的上升，採購團隊和生產商會透過尋找替代供應商、轉移生產或重新設計包裝來應對關稅上漲的影響。

透過細分市場洞察，揭示配方便利性、給藥方式和患者人口統計特徵等因素如何相互交織，進而影響臨床和採購優先事項。

細分市場能夠提供細緻的洞察，從而指導產品開發、臨床應用和籌資策略。基於適應症的頻譜涵蓋範圍廣泛，從需要高度微生物學精準度的血流感染疾病（包括原發性和繼發性菌血症）到下呼吸道感染疾病（包括社區獲得性肺炎、醫院獲得性肺炎和人工呼吸器相關性肺炎，這些感染通常需要住院重症監護資源和複雜的給藥技術）。皮膚和軟組織感染疾病（包括蜂窩組織炎組織炎、手術部位感染和傷口感染）凸顯了靈活給藥策略的必要性，這些策略既適用於住院也適用於門診病人。同時，尿道感染尿道感染（分為複雜性和非複雜性）則凸顯了標靶藥物管理和門診治療模式的機會。

影響美洲、歐洲、中東和非洲以及亞太地區臨床應用、採購行為和生產重點的區域趨勢

區域趨勢將對粘菌素甲磺酸鈉注射液的臨床實踐、法律規範和供應鏈策略產生重大影響。在美洲，醫療機構的抗菌藥物管理框架和大規模綜合醫療網路創造了一個以數據為導向、並與抗菌藥物通訊協定緊密結合的環境。醫院和專業輸液中心重視抗菌藥物管理的協調一致、臨床醫生教育和供應可靠性。合約機制和集團採購組織在採購中發揮重要作用，促使供應商在商業性談判中優先考慮服務水準、交貨保證和品質指標。

公司策略強調無菌生產卓越性、配方創新、夥伴關係模式和差異化商業服務，以贏得臨床試驗點和採購部門的信任。

硫酸粘菌素鈉注射液市場的競爭格局由成熟的無菌注射劑生產商、非專利公司以及專注於無菌填充和包裝的專業契約製造(CMO) 組成。現有生產商強調合規性、供應穩定性以及臨床支援服務是其差異化優勢，並投資於品質系統和審核準備工作，以滿足醫院的採購要求。同時，學名藥生產商和小型供應商則在價格和區域分銷方面競爭，同時面臨維持無菌注射產品所需高品質標準的壓力。

針對製造商和供應商的具體策略建議，以加強供應鏈韌性、擴大產品組合併深化臨床夥伴關係。

產業領導者可以透過實施有針對性的策略行動，果斷應對不斷變化的市場環境。他們優先投資於無菌注射劑生產能力和品質體系，以減少對集中式供應鏈的依賴，並能夠快速回應需求衝擊。同時，他們利用多供應商策略和區域合作夥伴，實現活性成分和包裝組件採購來源多元化，從而降低地緣政治和關稅風險。

我們採用了穩健的混合調查方法，結合了對臨床和採購相關人員的初步訪談、有針對性的文獻綜述、監管分析和資料檢驗。

本執行摘要的調查方法採用了一種三角測量法，結合了與主要相關人員的對話、有針對性的二手研究以及嚴格的資料檢驗。主要數據是透過與感染疾病醫生、醫院藥劑師、採購負責人以及生產和監管專家進行結構化訪談和諮詢收集的，旨在了解實際使用模式、採購需求和生產限制。這些對話有助於建立關鍵的臨床應用案例，推薦給藥方式，並識別與無菌注射劑生產和分銷相關的營運挑戰。

關鍵性綜合分析強調了實現永續取得所需的供應韌性、製劑創新、管理協作以及有針對性的臨床證據。

總之，注射用粘菌素鈉仍是複雜臨床環境下治療嚴重革蘭氏陰性菌病菌感染的重要治療方法。抗菌藥物抗藥性的日益增強、抗菌藥物管理計畫的日益成熟以及醫療服務模式的不斷變化，凸顯了建立穩健的供應鏈、研發臨床適用的製劑以及加強生產商與醫療服務提供者之間協作的重要性。儘管醫院和加護病房仍然是需求中心，但門診輸液服務和專科診所也不斷擴展，為注射治療提供更多選擇。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 粘菌素甲磺酸鹽注射液市場依適應症分類

  • 血液感染疾病
    • 原發性菌血症
    • 續發性菌血症
  • 下呼吸道感染疾病
    • 社區型肺炎
    • 院內肺炎
    • 人工呼吸器相關性肺炎
  • 皮膚和軟組織感染疾病
    • 蜂窩組織炎
    • 手術部位感染
    • 傷口感染疾病
  • 尿道感染
    • 複雜性尿道感染
    • 單純性尿道感染

9. 甲磺酸磺酸鹽鈉注射液市場（以劑型分類）

  • 凍乾粉
    • 多劑量管瓶
    • 單劑量管瓶
  • 即用型解決方案
    • 點滴袋
    • 預填充式注射器

10. 依患者族群分類的甲磺酸磺酸鹽鈉注射液市場

  • 成人
  • 老年人
  • 兒童
    • 青春期
    • 兒童
    • 嬰兒
    • 新生

11. 甲磺酸磺酸鹽注射劑市場依給藥途徑分類

  • 吸入
  • 肌肉內注射
  • 靜脈注射
    • 持續輸注
    • 間歇輸注

12. 依最終用戶分類的甲磺酸磺酸鹽鈉注射液市場

  • 門診治療中心
  • 診所
    • 門診部
    • 專科部門
  • 醫院
    • 普通病房
    • 加護病房

13. 各地區粘菌素甲磺酸鹽注射液市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 注射用甲磺酸磺酸鹽鈉市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各國粘菌素甲磺酸鹽注射液市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國注射甲磺酸磺酸鹽鈉市場

17. 中國注射甲磺酸鈉磺酸鹽市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott
  • Fresenius Kabi AG
  • Gland Pharma Limited
  • Hikma Pharmaceuticals PLC
  • Lupin Limited
  • Pfizer Inc.
  • Sagent Pharmaceuticals, Inc.
  • Sandoz International GmbH
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Limited
Product Code: MRR-4F7A6D4FF33A

The Colistimethate Sodium for Injection Market was valued at USD 50.54 million in 2025 and is projected to grow to USD 58.89 million in 2026, with a CAGR of 11.81%, reaching USD 110.43 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 50.54 million
Estimated Year [2026] USD 58.89 million
Forecast Year [2032] USD 110.43 million
CAGR (%) 11.81%

A detailed introduction to colistimethate sodium injections emphasizing clinical roles, administration pathways, formulation choices, and patient care settings

Colistimethate sodium for injection occupies a distinctive role in contemporary infectious disease management, primarily as a therapeutic option reserved for difficult-to-treat Gram-negative infections. Its pharmacological profile and clinical utility are particularly relevant in settings where multi-drug resistance limits the effectiveness of first-line agents. Historically positioned as a salvage therapy, colistimethate sodium has evolved in clinical practice through refinements in dosing strategies, administration modalities, and an expanded understanding of patient populations that derive the greatest benefit.

Clinically, its applications encompass a spectrum of severe infections including bloodstream infections, lower respiratory tract infections, skin and soft tissue infections, and urinary tract infections. Within these indications, specific clinical presentations such as primary and secondary bacteremia; community-acquired, hospital-acquired, and ventilator-associated pneumonias; cellulitis, surgical site, and wound infections; and both complicated and uncomplicated urinary tract infections require nuanced therapeutic decision making. These distinctions drive differential needs for dosing regimens, monitoring parameters, and supportive care pathways.

From an administration standpoint, clinicians choose among inhalation, intramuscular, and intravenous routes, with intravenous delivery further stratified into continuous and intermittent infusion methods to optimize pharmacokinetic and pharmacodynamic targets. Formulation choices influence clinical workflows: lyophilized powders-available in multi-dose and single-dose vials-remain important for stability and cold-chain considerations, while ready-to-use solutions such as infusion bags and prefilled syringes are increasingly valued for workflow efficiency and reduced preparation error. End users range from ambulatory care centers and clinics, including outpatient and specialty clinic settings, to hospitals where general wards and intensive care units present the highest demand and the most complex administration scenarios. Patient populations span adult, geriatric, and pediatric cohorts, with pediatric care further delineated into adolescent, child, infant, and neonatal groups, each of which imposes specific dosing and safety imperatives.

Taken together, these clinical, formulation, and care-setting dimensions define the practical landscape in which product developers, hospital pharmacists, and policymakers operate. The interplay of antimicrobial stewardship priorities, evolving resistance patterns, and operational constraints within hospitals continues to shape how colistimethate sodium is prescribed, prepared, and administered in contemporary clinical practice.

Transformative shifts driven by antimicrobial resistance, stewardship integration, formulation innovation, and heightened supply chain resilience expectations

The landscape for colistimethate sodium is shifting under several convergent forces that are transforming clinical practice, supply chains, and commercial strategies. Antimicrobial resistance trends remain the primary clinical driver, compelling physicians and institutions to preserve efficacy by refining dosing algorithms and integrating therapeutic drug monitoring where feasible. Concurrently, antimicrobial stewardship programs have matured from advisory roles into active gatekeepers of formulary access, influencing utilization patterns and encouraging the use of optimized administration approaches such as continuous infusion in select critically ill patients to maximize pharmacodynamic exposure while reducing toxicity risk.

Technological and formulation advances are reshaping how injectable antibiotics are deployed in hospitals and ambulatory settings. The trend toward ready-to-use solutions supports faster bedside administration and reduces compounding risk, which is particularly attractive in high-acuity units and outpatient infusion centers. Simultaneously, renewed interest in inhalation delivery for respiratory infections highlights the clinical community's willingness to explore localized therapies that may deliver higher pulmonary concentrations with potentially reduced systemic exposure. These therapeutic shifts are paralleled by manufacturing innovations, including improvements in sterile injectable production, packaging that extends product stability, and processes that enable smaller batch sizes to serve niche indications.

On the commercial front, supply chain resilience has moved to the forefront of strategic planning. Fabrication of active pharmaceutical ingredients, the geographic concentration of sterile injectable facilities, and regulatory inspections all influence product availability. As a result, organizations are increasingly prioritizing supplier diversification, on-site quality assurance, and partnerships with contract manufacturing organizations to mitigate disruption risk. Regulatory and procurement environments are evolving too; payers and hospital group purchasing organizations are applying more rigorous evaluation criteria tied to product risk management and lifecycle support. Consequently, companies that align clinical evidence generation, formulation convenience, and supply reliability are positioned to achieve greater acceptance among clinicians and procurement stakeholders.

Finally, patient-centric care models and the expansion of outpatient parenteral antimicrobial therapy are changing where treatments are delivered. With appropriate safety nets and training, selected indications historically managed in inpatient settings are now treated in ambulatory care centers or specialty clinics, reshaping demand profiles across care settings and accelerating the need for formulations that balance stability, ease of administration, and safety.

Cumulative effects of recent tariff shifts on supply chains, sourcing strategies, purchasing dynamics, and domestic manufacturing incentives for sterile injectables

Policy changes in tariff regimes and cross-border trade dynamics have tangible operational consequences for the supply chain of sterile injectables, and colistimethate sodium is not immune to these pressures. Alterations in tariff structures for active pharmaceutical ingredients, excipients, and packaging components can increase landed costs for finished product and create incentives for manufacturers to reassess sourcing strategies. When import costs rise, procurement teams and manufacturers respond by exploring alternative suppliers, shifting production footprints, or reconfiguring packaging to reduce exposure to tariff escalations.

The cumulative effects of tariff adjustments reverberate through contract negotiations, inventory strategies, and capital allocation. Healthcare providers and group purchasing entities may face higher acquisition costs, which in turn prompts more stringent tender evaluations and a greater emphasis on contractual guarantees for supply continuity. Manufacturers facing higher input costs often evaluate whether to absorb marginal increases, adjust list pricing, or renegotiate distribution agreements. In some cases, tariff volatility accelerates investment in onshore or near-shore production capabilities to mitigate future trade-policy risk and secure critical sterile manufacturing capacity.

From a clinical operations perspective, tariff-driven cost pressures can influence formulary decisions and the prioritization of stewardship interventions. Hospitals may intensify utilization review for high-cost injectables, seek therapeutic alternatives where clinically appropriate, or consolidate purchasing across health systems to restore negotiating leverage. For small suppliers and generic players, higher import duties may constrain margins and impede the ability to scale sterile production, potentially reducing competition over time and increasing dependence on a narrower set of suppliers.

In sum, changes in tariff policy reverberate across commercial and clinical domains: they affect sourcing strategies, contractual dynamics, and the incentives to invest in domestic manufacturing. Stakeholders who proactively map tariff exposure, diversify supplier bases, and engage in scenario planning will be better positioned to maintain supply continuity and preserve therapeutic options for patients reliant on colistimethate sodium injections.

Segmentation insights revealing where formulation convenience, administration modality, and patient cohort specificity converge to shape clinical and procurement priorities

Segmentation drives nuanced insights that inform product development, clinical adoption, and procurement strategies. Based on indication, the spectrum spans bloodstream infections-where primary and secondary bacteremia presentations demand heightened microbiological precision-and lower respiratory tract infections, including community-acquired, hospital-acquired, and ventilator-associated pneumonias that often require inpatient critical care resources and advanced delivery methods. Skin and soft tissue infections, encompassing cellulitis, surgical site infections, and wound infections, highlight the need for flexible dosing strategies suitable for both inpatient and outpatient management, whereas urinary tract infections, differentiated into complicated and uncomplicated cases, underscore opportunities for targeted stewardship and outpatient therapy models.

When examined through the lens of route of administration, intravenous delivery remains pivotal in acute care, with continuous infusion increasingly employed to meet pharmacodynamic goals in critically ill patients while intermittent infusion retains relevance where nursing workflows and monitoring frameworks favor established practice patterns. Inhalation delivery presents a complementary strategy for pulmonary infections, offering localized drug delivery that can be particularly relevant in mechanically ventilated patients, while intramuscular options are less prominent but important in resource-constrained scenarios or settings without IV access.

Formulation segmentation reveals competing priorities between stability and convenience. Lyophilized powders, offered in multi-dose and single-dose vials, continue to be valued for shelf life and transport resilience, particularly in settings lacking sophisticated cold-chain infrastructure, whereas ready-to-use solutions in infusion bags and prefilled syringes reduce preparation time and compounding risk, improving safety and throughput in busy infusion units and ambulatory centers.

End-user segmentation points to hospitals-especially intensive care units and general wards-as primary centers of clinical demand, where high acuity drives immediate need for reliable sterile supplies and robust clinical support. Clinics, including outpatient and specialty clinics, are expanding their role through outpatient parenteral antimicrobial therapy programs that shift certain treatment episodes out of the hospital. Ambulatory care centers similarly contribute to demand growth for formulations that support safe home or clinic administration.

Patient population segmentation emphasizes differentiated clinical needs: adults and geriatric patients often present with comorbidities and altered pharmacokinetics requiring careful monitoring, while pediatric care, spanning adolescents, children, infants, and neonates, introduces additional complexity in dosing calculations, safety monitoring, and formulation tolerability. These patient distinctions necessitate tailored clinical evidence, dosing guidance, and packaging that supports safe use across the lifespan.

Synthesizing these segmentation layers reveals where product innovation and commercial focus can have the greatest impact: formulations that reconcile stability with administration efficiency, dosing strategies that account for special populations, and supply models that align with the procurement realities of high-acuity hospitals and expanding outpatient infusion services.

Regional dynamics shaping clinical adoption, procurement behaviors, and manufacturing priorities across the Americas, EMEA, and Asia-Pacific landscapes

Regional dynamics materially influence clinical practice, regulatory oversight, and supply-chain strategies for colistimethate sodium injections. In the Americas, institutional stewardship frameworks and large integrated delivery networks create environments where formulary decisions are data driven and closely tied to antimicrobial protocols; hospitals and specialty infusion centers place a premium on stewardship alignment, clinician education, and supply reliability. Contracting mechanisms and group purchasing organizations play influential roles in procurement, prompting suppliers to prioritize service levels, delivery guarantees, and quality metrics in commercial discussions.

In Europe, the Middle East, and Africa, heterogeneity in regulatory regimes and healthcare financing models produces a mosaic of adoption patterns. Certain jurisdictions emphasize centralized procurement and stringent regulatory oversight, encouraging the uptake of well-documented generics and formulations that meet high standards for sterility and stability. In contrast, regions with constrained infrastructure may rely more heavily on lyophilized forms that tolerate variable storage conditions. Across these territories, public health initiatives and regional antimicrobial resistance programs inform utilization and access strategies.

The Asia-Pacific region presents a complex interplay of high infectious disease burden, variable regulatory maturity, and substantial manufacturing capacity. The prevalence of multi-drug-resistant organisms in several countries drives intensive clinical use in hospitals and ICUs, while strong pharmaceutical manufacturing ecosystems support both active pharmaceutical ingredient production and finished sterile injectable manufacturing. These capabilities create opportunities for localized production and export, but they also mean that policy shifts-such as tariffs or import controls-can rapidly alter global supply flows. Emerging outpatient care models in urban centers and increased investment in hospital infrastructure further shape demand for ready-to-use formulations and reliable sterile supply chains.

Across regions, differences in clinical practice, procurement frameworks, and manufacturing capacity determine where companies should focus evidence generation, formulation development, and commercial support. Understanding these regional nuances is essential for aligning product portfolios with the operational realities and clinical priorities of diverse healthcare systems.

Company strategies emphasizing sterile manufacturing excellence, formulation innovation, partnership models, and commercial service differentiation to secure clinical and procurement trust

Competitive dynamics in the injectable colistimethate sodium space reflect a blend of established sterile injectable manufacturers, generic players, and specialized contract manufacturers focused on sterile fill-finish capabilities. Established manufacturers emphasize regulatory compliance, consistent supply, and clinical support services as differentiators, investing in quality systems and audit readiness to meet hospital procurement expectations. Generics and smaller suppliers often compete on price and regional distribution strength, while facing pressure to maintain the high quality standards required for sterile injectable products.

Strategic behavior among companies includes investment in ready-to-use formats to capture hospital preference for reduced compounding risk, partnerships with contract manufacturing organizations to scale sterile capacity without excessive capital expenditure, and selective geographic expansion into regions with high clinical need or manufacturing synergies. Lifecycle management strategies are also prominent: suppliers pursue incremental innovations such as improved stability packaging, prefilled syringe platforms, and patient-centric dosing aids that streamline administration in outpatient or home settings.

Mergers, acquisitions, and strategic alliances are deployed to secure access to critical sterile capacity, particularly where barrier-to-entry costs and regulatory expectations are substantial. Supply reliability has become a commercial offering in itself, with companies differentiating on guaranteed fill rates, expedited logistics, and integrated quality reporting to procurement partners. Additionally, firms are increasingly investing in clinical education and stewardship engagement to support appropriate use and to build trust with institutional customers.

Taken together, these company-level priorities underline a clear imperative: success hinges on the ability to combine regulatory rigor, manufacturing resilience, clinically relevant formulation innovation, and proactive commercial support that addresses the operational pain points of hospitals and outpatient infusion providers.

Actionable strategic recommendations for manufacturers and providers to strengthen supply resilience, advance formulation portfolios, and deepen clinical partnerships

Industry leaders can respond decisively to the evolving landscape by implementing a focused set of strategic actions. Prioritize investment in sterile injectable manufacturing capacity and quality systems to reduce reliance on concentrated supply chains and enable faster responses to demand shocks. Concurrently, diversify sourcing of active pharmaceutical ingredients and packaging components, employing multi-vendor strategies and regional partners to lower geopolitical exposure and tariff risk.

Develop and accelerate ready-to-use formulations while maintaining lyophilized options for markets with cold-chain or stability constraints. By offering a portfolio that balances stability with administration efficiency, companies can address the needs of intensive care units, ambulatory infusion centers, and outpatient parenteral therapy programs. Pair formulation advances with clinical evidence generation tailored to special populations, including geriatrics and pediatric subgroups, to ensure prescriber confidence and to meet regulatory expectations in diverse jurisdictions.

Engage proactively with antimicrobial stewardship committees, hospital pharmacists, and physician champions to co-design educational programs, dosing guidelines, and therapeutic monitoring protocols. These collaborations will facilitate appropriate use, reduce potential toxicity concerns, and reinforce the supplier's role as a clinical partner rather than a vendor. On the commercial side, negotiate service-level agreements that emphasize supply guarantees, expedited logistics, and post-sale technical support to meet the procurement priorities of large health systems and group purchasing organizations.

Finally, embed tariff and regulatory scenario planning into commercial strategy. Model the implications of trade policy shifts on landed costs, and evaluate the feasibility of near-shore production or strategic stockpiles where clinically appropriate. These measures, combined with targeted investment in formulation innovation and stakeholder engagement, will strengthen resilience and create competitive differentiation that supports long-term access to this critical injectable therapy.

Robust mixed methods research approach combining primary clinical and procurement interviews, targeted literature review, regulatory analysis, and data triangulation

The research methodology underpinning this executive summary employed a triangulated approach combining primary stakeholder engagement, targeted secondary research, and rigorous data validation. Primary inputs were obtained through structured interviews and consultations with infectious disease clinicians, hospital pharmacists, procurement officers, and manufacturing and regulatory experts to capture real-world practice patterns, procurement imperatives, and manufacturing constraints. These conversations informed the framing of key clinical use cases, preferred administration modalities, and the operational challenges associated with sterile injectable production and distribution.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, public policy releases, and quality-assurance standards relevant to sterile injectable manufacturing and antimicrobial stewardship. Where applicable, company disclosures, product labeling, and public inspection reports were analyzed to corroborate claims about formulation attributes and manufacturing footprints. Regulatory databases were reviewed to understand approval pathways and post-market surveillance dynamics that affect clinical adoption.

Methodological rigor was maintained through cross-validation of primary and secondary findings, scenario analysis to assess the impact of trade and tariff changes, and sensitivity checks on supply chain assumptions. Stakeholder feedback loops ensured that interpretations of clinical practice and procurement behavior accurately reflected operational realities. Limitations of the methodology include variability in regional reporting standards and the inherent lag between guideline updates and bedside practice change, which were mitigated by prioritizing recent expert interviews and contemporaneous regulatory materials.

Ethical standards and confidentiality protocols were observed during primary data collection, and proprietary information shared by interviewees was handled in accordance with agreed non-disclosure terms. This mixed-methods approach yields a robust synthesis of clinical, commercial, and regulatory factors that inform practical decision making.

Conclusive synthesis highlighting the need for supply resilience, formulation innovation, stewardship collaboration, and targeted clinical evidence for sustained access

In conclusion, colistimethate sodium for injection remains an essential therapeutic tool for addressing severe Gram-negative infections in complex clinical settings. The interplay of rising antimicrobial resistance, maturation of stewardship programs, and changing care delivery models underscores the need for resilient supply chains, clinically relevant formulations, and collaborative engagement between manufacturers and healthcare institutions. Hospitals and intensive care units continue to be focal points of demand, while outpatient infusion services and specialty clinics are expanding the contexts in which injectable therapy is delivered.

Commercially, companies that invest in sterile manufacturing excellence, diversify sourcing, and offer formulations that align with frontline workflow imperatives will be best positioned to meet institutional needs. Regulatory and tariff environments add layers of complexity that require proactive scenario planning and potential near-shore capacity investments. From a clinical standpoint, tailored dosing guidance and evidence generation for special populations will be critical to ensure safe, effective, and guideline-concordant use across the lifespan.

Overall, the strategic priorities are clear: strengthen supply resilience, innovate in formulation and delivery to reduce compounding risk, and partner closely with stewardship programs and procurement stakeholders to secure appropriate, sustainable access to this vital injectable therapy. Acting on these imperatives will help preserve therapeutic options for patients facing severe, hard-to-treat infections.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Colistimethate Sodium for Injection Market, by Indication

  • 8.1. Bloodstream Infection
    • 8.1.1. Primary Bacteremia
    • 8.1.2. Secondary Bacteremia
  • 8.2. Lower Respiratory Tract Infection
    • 8.2.1. Community Acquired Pneumonia
    • 8.2.2. Hospital Acquired Pneumonia
    • 8.2.3. Ventilator Associated Pneumonia
  • 8.3. Skin And Soft Tissue Infection
    • 8.3.1. Cellulitis
    • 8.3.2. Surgical Site Infection
    • 8.3.3. Wound Infection
  • 8.4. Urinary Tract Infection
    • 8.4.1. Complicated Urinary Tract Infection
    • 8.4.2. Uncomplicated Urinary Tract Infection

9. Colistimethate Sodium for Injection Market, by Dosage Form

  • 9.1. Lyophilized Powder
    • 9.1.1. Multi Dose Vial
    • 9.1.2. Single Dose Vial
  • 9.2. Ready To Use Solution
    • 9.2.1. Infusion Bag
    • 9.2.2. Prefilled Syringe

10. Colistimethate Sodium for Injection Market, by Patient Population

  • 10.1. Adult
  • 10.2. Geriatric
  • 10.3. Pediatric
    • 10.3.1. Adolescent
    • 10.3.2. Child
    • 10.3.3. Infant
    • 10.3.4. Neonatal

11. Colistimethate Sodium for Injection Market, by Route Of Administration

  • 11.1. Inhalation
  • 11.2. Intramuscular
  • 11.3. Intravenous
    • 11.3.1. Continuous Infusion
    • 11.3.2. Intermittent Infusion

12. Colistimethate Sodium for Injection Market, by End User

  • 12.1. Ambulatory Care Center
  • 12.2. Clinic
    • 12.2.1. Outpatient Clinic
    • 12.2.2. Specialty Clinic
  • 12.3. Hospital
    • 12.3.1. General Ward
    • 12.3.2. Intensive Care Unit

13. Colistimethate Sodium for Injection Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Colistimethate Sodium for Injection Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Colistimethate Sodium for Injection Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Colistimethate Sodium for Injection Market

17. China Colistimethate Sodium for Injection Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott
  • 18.6. Fresenius Kabi AG
  • 18.7. Gland Pharma Limited
  • 18.8. Hikma Pharmaceuticals PLC
  • 18.9. Lupin Limited
  • 18.10. Pfizer Inc.
  • 18.11. Sagent Pharmaceuticals, Inc.
  • 18.12. Sandoz International GmbH
  • 18.13. Teva Pharmaceutical Industries Ltd.
  • 18.14. Viatris Inc.
  • 18.15. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PRIMARY BACTEREMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SECONDARY BACTEREMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMMUNITY ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL ACQUIRED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY VENTILATOR ASSOCIATED PNEUMONIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CELLULITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SURGICAL SITE INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY WOUND INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COMPLICATED URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY UNCOMPLICATED URINARY TRACT INFECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFUSION BAG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PREFILLED SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INFANT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY NEONATAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CONTINUOUS INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTERMITTENT INFUSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY AMBULATORY CARE CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY OUTPATIENT CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SPECIALTY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 167. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 169. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 215. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 217. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 218. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 219. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 220. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 231. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 232. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 233. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 234. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 235. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 236. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 237. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 247. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 248. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 249. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 250. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 251. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 252. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 253. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 254. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INTRAVENOUS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY CLINIC, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY HOSPITAL, 2018-2032 (USD MILLION)
  • TABLE 263. GLOBAL COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY BLOODSTREAM INFECTION, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LOWER RESPIRATORY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY SKIN AND SOFT TISSUE INFECTION, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY URINARY TRACT INFECTION, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY LYOPHILIZED POWDER, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY READY TO USE SOLUTION, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY PATIENT POPULATION, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN COLISTIMETHATE SODIUM FOR INJECTION MARKET SIZE, BY